Boston Therapeutics, Inc. – OTC:BTHE

Boston Therapeutics, Inc., a pre-clinical and clinical-stage pharmaceutical development company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements in the United States. Its lead pharmaceutical drug candidates are BTI-320, a non-systemic carbohydrate-based compound that is in Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic and pre diabetic patients; BTI-410, a peptide injectable compound that has completed Phase Ib clinical trials for type 1 immunosuppression therapy after kidney transplant surgery and type 2 diabetes patients; and IPOXYN, a carbohydrate-based injectable drug to prevent necrosis, or cell death, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications. The company also produces and sells SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement to support healthy post-meal blood glucose. The company was formerly known as Avanyx Therapeutics, Inc. and changed its name to Boston Therapeutics, Inc. in November 2010. Boston Therapeutics, Inc. was founded in 2009 and is headquartered in Lawrence, Massachusetts.